logo

Pulmatrix Inc. (PULM)



Trade PULM now with
  Date
  Headline
5/14/2020 9:07:22 AM Pulmatrix Q1 Net Loss $4.7 Mln Vs. Loss $5.2 Mln Prior Year
3/26/2020 9:05:17 AM Pulmatrix 2019 Revenue Rises To $7.9 Mln From $0.2 Mln Prior Year
1/30/2020 8:13:13 AM Pulmatrix: FDA Grants Fast Track Designation For Pulmazole For The Treatment Of Asthma-ABPA
1/16/2020 12:30:05 PM Pulmatrix Regains Compliance With Nasdaq Minimum Bid Price Requirement
1/2/2020 8:52:30 AM Pulmatrix Enters Licensing And Development Agreement With The Lung Cancer Initiative At Johnson & Johnson
11/1/2019 9:05:53 AM Pulmatrix Q3 Net Loss $3.6 Mln Vs. Loss $4.8 Mln Prior Year
9/18/2019 9:31:59 AM Pulmatrix: First Patient Dosed In Phase 2 Trial Evaluating Pulmazole For Treatment Of ABPA In Patients With Asthma
8/19/2019 9:28:50 AM Pulmatrix Receives Grant From USPTO For US Pat. No. 10376465
8/5/2019 9:04:03 AM Pulmatrix Q2 Net Loss $7.8 Mln Vs.net Loss $6.2 Mln Prior Year
5/16/2019 9:15:35 AM Pulmatrix CEO Robert Clarke Steps Down
4/3/2019 9:34:06 PM Pulmatrix Announces Pricing Of $14.4 Million Upsized Public Offering
3/12/2019 12:28:31 PM Pulmatrix Regains NASDAQ Compliance
2/8/2019 7:07:31 AM Pulmatrix Announces $2.5 Mln Registered Direct Offering Priced At-the-Market
2/7/2019 9:04:29 AM Pulmatrix Gets IND Approval For Pulmazole Phase 2 Clinical Study
2/5/2019 12:45:56 PM Pulmatrix Announces 1-for-10 Reverse Stock Split